Comparing reduced port laparoscopic gastrectomy to traditional methods for gastric cancer
Comparison the Short and Long-term Outcome of Patients With Gastric Cancer Who Underwent Reduced Port Laparoscopic Gastrectomy With Patients Underwent Traditional Laparoscopic Gastrectomy
This study tests if a new way of doing stomach surgery with fewer small cuts is safer and works better for people with gastric cancer compared to the usual method.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Nanchong Central Hospital Government |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Nanchong, Sichuan) |
| Trial ID | NCT04295473 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and outcomes of reduced port laparoscopic gastrectomy in patients with gastric cancer compared to traditional laparoscopic gastrectomy. It aims to assess both short-term outcomes, such as surgical complications and postoperative nutrition, and long-term outcomes, including survival rates. The study involves patients with histologically confirmed adenocarcinoma of the stomach and will systematically analyze the results to determine the effectiveness of the reduced port approach.
Who should consider this trial
Good fit: Ideal candidates are patients with histologically confirmed adenocarcinoma of the stomach at stages T1-T4 and an Eastern Cooperative Oncology Group performance status of 0 or 1.
Not a fit: Patients with distant metastasis, significant oesophageal invasion, or those who have received prior chemotherapy or radiation therapy for other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and recovery for patients undergoing gastrectomy for gastric cancer.
How similar studies have performed: While reduced port laparoscopic techniques are gaining traction, systematic evaluations comparing them to traditional methods are still limited, making this study a potentially novel contribution.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the stomach, T1-T4 stages. 2. Eastern Cooperative Oncology Group performance status of 0 or 1. 3. Adequate organ function. Exclusion Criteria: 1. Patients had distant metastasis. 2. oesophageal invasion of more than 3 cm. 3. Borrmann type 4 or large (more than 8 cm) type 3 carcinoma. 4. Previous chemotherapy or radiation therapy for any other malignancies.
Where this trial is running
Nanchong, Sichuan
- Yunhong Tian — Nanchong, Sichuan, China (Recruiting)
Study contacts
- Principal investigator: Yunhong Tian, MD — Nanchong Central Hospital
- Study coordinator: Yunhong Tian, MD
- Email: drtianyunhong@126.com
- Phone: +86-13508087719
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.